Cardiovascular and Metabolic diseases
Following the science to help people maintain and improve cardiovascular and metabolic health
An enduring, bold ambition to break through conventional thinking in cardiovascular and metabolic health
AstraZeneca has a patient-centric approach to disease treatment, so we are tackling multiple risk factors by uniting our cardiovascular (CV), metabolic and chronic kidney disease (CKD) disease areas into one integrated approach – cardiovascular and metabolic disease (CVMD).
This approach means we look at the CVMD patient as a whole, rather than by disease area, because we know that cardiovascular disease (CVD) is a well-known consequence of diabetes and CKD. Each of our focus areas seek to further reduce cardiovascular morbidity and mortality, and organ damage by addressing multiple CV risk factors.
AstraZeneca has been driving CV innovation for more than 100 years. As we aim to break through conventional thinking by following what the science is telling us, we will:
- continue to build our CV and diabetes portfolio to help a broader range of patients
- focus on investigating the impact of treatment options on reducing CV events and death in a broad range of high-risk patients, beyond acute coronary syndromes (ACS)
- shift the treatment paradigm of Type 2 diabetes to early combination therapy and accelerate achievement of treatment goals
- develop new therapies for anaemia in people with CKD.
Our enduring goal is to push the boundaries of science to deliver life-changing medicines to the people who need them, and contribute to improved health for millions more people around the world.
Our focus on unmet needs
Cardiovascular disease is responsible for 30% of all deaths globally, one in three deaths in the US and more than half of all deaths across Europe.
Acute coronary syndromes, which include heart attack and unstable angina, are responsible for almost half of all deaths worldwide related to cardiovascular disease.
Diabetes is a growing disease and an enormous global burden that is currently projected to affect more than 592 million people by the year 2035.
Chronic kidney disease is a complex, debilitating condition that affects more than 70 million people worldwide and more than 20 million adults in the US.
What we're working on
As part of our commitment to CVMD, here you can find highlights of our key areas of focus.
A proactive approach to diabetes
Approximately 50% of patients with Type 2 diabetes fail to achieve recommended blood sugar levels. AstraZeneca is committed to shifting the treatment paradigm to early combination therapy to support early intervention and achievement of treatment goals.
Chronic kidney disease
AstraZeneca and MedImmune are building a portfolio and early research programme in chronic kidney disease (CKD), with studies underway to understand how complications of kidney disease and fluid status may be mitigated to improve outcomes. As such, AstraZeneca and FibroGen are collaborating on the development and commercialisation of roxadustat (FG-4592) for the treatment of anaemia in patients with CKD in the US, China and all major markets, excluding those which are covered by the collaboration between Astellas and FibroGen. Astellas and FibroGen are collaborating on the development and commercialisation of roxadustat in Europe, Japan, the Commonwealth of Independent States, Middle East and South Africa.
Tackling CV risk
AstraZeneca is evaluating the potential of Epanova (omega-3-carboxylic acids), a novel omega-3 free fatty acid formulation. The ongoing STRENGTH trial will assess the long-term efficacy and safety of Epanova in 13,000 patients at increased cardiovascular risk despite optimal statin treatment.
PARTHENON is the comprehensive, long-term, evolving global research initiative intended to address unanswered questions in atherothrombotic disease and to investigate the impact of ticagrelor (Brilinta/Brilique) on reducing cardiovascular (CV) events and death. It is AstraZeneca’s largest clinical trial programme, involving more than 80,000 patients at high risk of CV events, in collaboration with more than 4,000 clinical investigators in more than 30 countries.
Our current pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.
Cardiovascular and Metabolic diseases (as at 10 November 2016)
Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.
Disease area resources
Brilique (ticagrelor) approved in EU for extended treatment of patients with history of heart attack
US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.